Rheumatoid Arthritis News

    Skip to content
    • Home
    • Treatments
      • Tofacitinib (Xeljanz)
    • Experimental Treatments
      • Piclidenoson
      • Kevzara (Sarilumab)
      • Baricitinib (Olumiant)
    • About Us
    • Contact Us
    •
      June 12, 2017August 24, 2022

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      Diplomat Pharmacy has begun filling prescriptions for Kevzara (sarilumab) for patients with moderate to severe rheumatoid arthritis (RA). The announcement comes after the U.S. Food and Drug ... Read more
    • June 7, 2017June 7, 2017

      Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      Active rheumatoid arthritis (RA) patients whose response to methotrexate (MTX) therapy was insufficient showed improvement when MTX was combined with filgotinib, an investigational JAK–1 inhibitor, according ... Read more
    • June 5, 2017June 5, 2017

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      The European Medicines Agency (EMA) has accepted a marketing authorization application from generic pharmaceuticals developer Sandoz for the review of biosimilars for AbbVie’s Humira (adalimumab) and Janssen’s Remicade (infliximab), ... Read more
    • June 2, 2017June 2, 2017

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      Results of a recent study showed that biological therapy regimens, such as Enbrel (etanercept), Humira (adalimumab), ‎Remicade (infliximab), ‎Simponi (golimumab), or ‎Cimzia (certolizumab), are less cost-effective ... Read more
    • May 23, 2017May 23, 2017

      Kevzara Approved by FDA for Treatment of RA in Adults Who Don’t Respond to DMARDs

      Kevzara (sarilumab) was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with moderate to severely active rheumatoid arthritis ... Read more
    JAK-1 Inhibitor, ABT-494, Seen to Aid RA Patients Now Advancing into Phase 3 Tests
    December 21, 2016December 21, 2016

    JAK-1 Inhibitor, ABT-494, Seen to Aid RA Patients Now Advancing into Phase 3 Tests

    News
    Recent results from a Phase 2b clinical trial evaluating the JAK-1 inhibitor, ABT-494, in patients with moderate to severe rheumatoid arthritis (RA) who did not respond to methotrexate (MTX) therapy show that, ... Read more
    Specific Bacterium May Be Link Between RA and Gum Disease, Study Finds
    December 19, 2016December 19, 2016

    Specific Bacterium May Be Link Between RA and Gum Disease, Study Finds

    News
    A bacterium that causes gum infections may also contribute to inflammation leading to chronic joint-destroying rheumatoid arthritis (RA), according to new research. This could provide useful information on how to ... Read more
    Less Than Half of Opiates Used by RA Patients Were Prescribed by Rheumatologist
    December 14, 2016December 14, 2016

    Less Than Half of Opiates Used by RA Patients Were Prescribed by Rheumatologist

    News
    New research indicates 43 percent of patients with rheumatoid arthritis (RA) who were prescribed opiates between 2006 and 2014 had their prescriptions written by a rheumatology specialist. These were the findings ... Read more
    University Recruiting Participants for Research Study on Effects of RA and Lupus
    December 12, 2016December 12, 2016

    University Recruiting Participants for Research Study on Effects of RA and Lupus

    News, rheumatoid arthritis
    Researchers at the Department of Communication Sciences and Disorders of East Stroudsburg University (ESU) in Pennsylvania are conducting a research study on the effects of rheumatoid arthritis (RA) and systemic lupus ... Read more
    T-cells May Predict Rituxan Treatment Response in RA Patients
    December 9, 2016December 9, 2016

    T-cells May Predict Rituxan Treatment Response in RA Patients

    News, rheumatoid arthritis
    Rheumatoid arthritis patients who benefit from Rituxan (rituximab) have a distinctive drop in T-cells after treatment — a change that corresponds to an improvement in symptoms. The findings show that counts ... Read more
    Report Highlights Deficiencies in Treatment of Arthritis Patients in Wales
    December 7, 2016December 7, 2016

    Report Highlights Deficiencies in Treatment of Arthritis Patients in Wales

    News, rheumatoid arthritis
    The British Society for Rheumatology (BSR) and the National Rheumatoid Arthritis Society (NRAS) have jointly issued the report, “Rheumatology in Wales: The State of Play,” exploring rheumatology services in Wales ... Read more
    Report Provides Information on 33 New Humira Biosimilar Therapy Candidates for RA
    December 5, 2016December 5, 2016

    Report Provides Information on 33 New Humira Biosimilar Therapy Candidates for RA

    News
    PNS Pharma recently released a report titled “Humira Biosimilars Clinical Trial Insight” that includes clinical data on 33 potential new drugs that have a similar action to Humira (adalimumab), an ... Read more
    Specific Fibroblasts Found to Promote Joint Damage in RA, Study Shows
    December 2, 2016December 2, 2016

    Specific Fibroblasts Found to Promote Joint Damage in RA, Study Shows

    News, rheumatoid arthritis
    Researchers at the University of Birmingham in England unraveled the key role of different types of fibroblasts — cells that synthesize extracellular matrix and collagen — in rheumatoid arthritis (RA). The study, ... Read more
    Children Born to Moms with Rheumatoid Arthritis at Risk for Epilepsy, Study Finds
    November 30, 2016November 30, 2016

    Children Born to Moms with Rheumatoid Arthritis at Risk for Epilepsy, Study Finds

    News, rheumatoid arthritis
    Children born to mothers with rheumatoid arthritis (RA) are at increased risk for developing epilepsy, new research shows. The study, “Parental rheumatoid arthritis and childhood epilepsy,” published in the journal ... Read more
    Genalyte’s Diagnostic Tool Shows Potential to Improve Turnaround Time in RA, Other Conditions
    November 29, 2016November 29, 2016

    Genalyte’s Diagnostic Tool Shows Potential to Improve Turnaround Time in RA, Other Conditions

    News, rheumatoid arthritis
    Genalyte recently presented promising data on its new Maverick Detection System, demonstrating its potential to be used in a near patient setting to improve turnaround time for test results and diagnosis for ... Read more

    Posts navigation

    Older posts
    Newer posts

    Never miss another RA update.

    * indicates required
    Bionews, Inc.
    3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363

    Recent Posts

    • Diplomat selling Kevzara

      Diplomat Pharmacy Begins Dispensing Kevzara to Treat Rheumatoid Arthritis

      June 12, 2017

    • Filgotinib Improves RA Patient Outcomes When Methotrexate Is Inadequate, Study Suggests

      June 7, 2017

    • Truxima, a biosimilar of rituximab

      EMA Accepts Humira and Remicade Biosimilars for Regulatory Review

      June 5, 2017

    • triple therapy

      DMARDs Triple Therapy Provides Better Cost-Effective First Line Strategy for RA, Study Finds

      June 2, 2017

    • About Us
    • Contact Us
    • Terms of Service
    • Privacy Policy

    Disclaimer:

    Rheumatoid Arthritis News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
    Copyright © 2013-2025 All rights reserved.